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Identi®cation of tissue-speci®c mechanisms involved
in the pathophysiology of in¯ammatory skin diseases
could offer new possibilities to develop effective
therapies with fewer systemic effects. The serine pro-
tease stratum corneum chymotryptic enzyme is pre-
ferentially expressed in cornifying epithelia. We have
previously reported on increased expression of the
stratum corneum chymotryptic enzyme in psoriasis.
Here is reported an increased epidermal expression
of stratum corneum chymotryptic enzyme also
found in chronic lesions of atopic dermatitis.
Transgenic mice expressing human stratum corneum
chymotryptic enzyme in suprabasal epidermal kera-
tinocytes were found to develop pathologic skin
changes with increased epidermal thickness, hyper-
keratosis, dermal in¯ammation, and severe pruritus.
The results suggest that stratum corneum chymo-
tryptic enzyme may be involved in the pathogenesis
of in¯ammatory skin diseases, and that stratum cor-
neum chymotryptic enzyme and related enzymes
should be evaluated as potential targets for new
therapies. Key words: itch/kallikrein/serine protease/
skin/transgenic mice. J Invest Dermatol 118:444±449, 2002
C
ommon in¯ammatory skin diseases may result in
severe handicap by causing reduced function,
stigmatization, and almost unbearable sensory symp-
toms. For many of these diseases available treatments
are still unsatisfactory. In conditions such as psoriasis
and atopic dermatitis there is good evidence in favor of a central
pathophysiologic role for the immune system (for reviews see
Nickoloff, 1999; Leung, 1999). It seems likely that the develop-
ment of the various disease-speci®c skin lesions and symptoms is the
result of interactions at the cellular and molecular level between the
immune system and skin-derived structures and molecules. Skin-
speci®c cells produce a wide variety of adhesion molecules,
cytokines, and growth factors by which they can communicate
with the immune system. This type of molecules are, however,
more or less generally present in cells and tissues throughout the
body. Accordingly, the most effective treatments in, for example,
psoriasis, which interfere with this type of general mechanism, do
not have skin-speci®c effects, and have limited usefulness due to
their systemic mode of action and unwanted side-effects. The
chances of ®nding more speci®c treatments for a given skin disease
could improve if one could ®nd skin-speci®c structures or
molecules involved in the pathogenesis of the disease.
Many of the tissue-speci®c molecular mechanisms of the skin are
associated with the formation and turnover of the barrier-forming
outermost layer of the epidermis, the stratum corneum, consisting
of corni®ed epithelial cells surrounded by highly organized lipids.
The stratum corneum is continuously being formed in the process
of epidermal differentiation. In our efforts to understand the
mechanisms by which a constant thickness of the stratum corneum
is maintained via a continuos desquamation of surface cells, we
identi®ed two new human serine proteases, stratum corneum
chymotryptic enzyme (SCCE; also named kallikrein 7) and stratum
corneum tryptic enzyme (SCTE; also named kallikrein 5) (Hansson
et al, 1994; Brattsand and Egelrud, 1999; Diamandis et al, 2000a;
Ekholm et al, 2000). Both enzymes belong to the kallikrein group
of serine proteases, the genes of which are localized to a short
stretch of chromosome 19q13.3±q13.4 (Diamandis et al, 2000b).
The expression of SCCE and SCTE seems to be restricted to
squamous epithelia undergoing corni®cation and in which there is a
need for desquamation (Ekholm et al, 2000). Results in this study
are reported to elucidate the possible involvement of one of these
proteases, SCCE, in skin pathology. We characterized the human
and murine scce genes, and produced transgenic mice over-
expressing human scce mRNA under a viral promoter. The only
phenotypic changes observed were found in the skin, which
showed several histologic changes similar to those seen in
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in¯ammatory skin diseases in humans. In addition, the transgenic
mice showed signs of severe itch. We also found evidence of
overexpression of SCCE in chronic lesions of atopic dermatitis in
humans, as we have recently shown for psoriasis (Ekholm and
Egelrud, 1999). Taken together, our results give support for the
idea that SCCE and related enzymes may be involved in the
pathophysiology of in¯ammatory skin diseases, and thus are
potential targets for organ-speci®c treatments.
MATERIALS AND METHODS
Human and murine scce genes The human scce (hscce) gene was
isolated from a human leukocyte genomic library (Clontech, Palo Alto,
CA) by using cDNA probes derived from the human scce cDNA
(Hansson et al, 1994). Overlapping clones were isolated and the entire
structural gene was sequenced and analyzed. (GenBank accession no.
AF332583; also see GenBank AF166330and Yousef et al, 2000)
To isolate the murine scce (mscce) gene cDNA probes derived from the
murine scce cDNA (BaÈckman et al, 1999) were used to screen and isolate
clones from a 129SVJ Lambda Fix II genomic library (Stratagene, La
Jolla, CA). The entire gene sequence was determined and constructed as
above (GenBank accession no. AF339930).
Transgenic mice The scce genomic DNA was modi®ed by insertion
of HindIII linkers 20 bp upstream of the start codon in exon 2, and
4.8 kb downstream of the stop codon, respectively. The resulting
HindIII scce fragment was then ligated to a 325 bp BamHI/HindIII
fragment containing the SV40e enhancer and promoter elements and
cloned into pBluescript SK+ (Stratagene), resulting in pAM119. For gene
transfer, the plasmid pAM119 was digested with BamHI and ClaI and
the SV40e/scce fragment of about 10.7 kb was isolated and puri®ed by
electroelution before microinjection into one-cell stage mouse fertilized
oocytes. Transgenic mice were generated in C57BL/6JxCBA-f2 embryos
by standard microinjection procedures (Hogan et al, 1986). Three
transgenic lines Tg103SV40e±hscce, Tg107SV40e±hscce and Tg1010SV40e±hscce)
were established by breeding heterozygous mice with C57BL/6JxCBA
or with C57BL/6J. Littermates were used as controls. To identify
transgenic animals, DNA was extracted from tail biopsies of 3 wk old
mice and analyzed by southern blot analyses or polymerase chain
reaction (PCR) with probes and primers designed to discriminate
between human and murine genomic scce DNA. Tissue specimens for
RNA or protein analyses were collected at different ages and
immediately frozen in liquid nitrogen. Specimens were also processed for
histologic analyses. The animal experiments had been approved by the
Regional Ethical Committee for Animal Experiments.
Skin biopsies These were taken from human volunteers and patients
after informed consent and with the approval of the Human Research
Ethics Committee, UmeaÊ University.
RNA isolation, cDNA synthesis, and real-time quantitative
PCR Total RNA were prepared from 50 to 300 mg of tissue using
RNA STAT-60 (Tel-Test ``B'', Friendswood, TX) according to the
manufacturer. From each RNA preparation 50 mg was DNase treated
(Ausubel et al, 1992) using RQ1 DNase (Promega, Madison, WI), and
about 1.6 mg total RNA from each tissue was used for cDNA synthesis.
From each tissue RNA samples from three animals with the same
genetic background were pooled. Superscript Pre-ampli®cation System
for First Strand cDNA Synthesis (Life Technologies, Gaithersburg, MD)
was used according to the manufacturer, using Oligo d(T)12±18 primer.
The synthesized cDNA was diluted 100 3 in water. Real-time
quanti®cation was performed in triplicate for each cDNA with primers
and probes derived from exons 4 and 5 of the hscce gene and designed to
discriminate between hscce and mscce genes: As forward primer (5¢-GCG-
AACCCCCTGGAACAA-3¢: position 427±444 of the human cDNA
sequence in exon 4); and reverse primer (5¢-ACATCCACGCAC-
ATGAGGTCA-3¢; position 490±510 of the human cDNA sequence in
exon 5) were used. The real-time ampli®cation probe (5¢-
CCTGTACTGTCTCCGGCTGGGGCACTACC-3¢; position 445±473
of the human cDNA sequence in exon 4), was labeled with the reporter
¯uorescent dye FAM in the 5¢-end and the quencher ¯uorescent dye
TAMRA in the 3¢-end. The ampli®cation of PCR products and real-
time detection were performed in ABI Prism 7700 Sequence Detection
System (PE Applied Biosystems, Foster City CA). Ampli®cation of a part
of murine acidic ribosomal phosphoprotein P0 (GenBank accession no.
X15267) was used as endogenous control for the real-time quanti®cation
studies. The relative quanti®cation was calculated according to the
formula: relative amount of mRNA = 2 ± DCT, where DCT is the
difference in threshold values between the target and the endogenous
control (User Bulletin 2, PE Applied Biosystems).
Protein and histologic analyses Polyclonal antibodies to recombinant
human SCCE were prepared and af®nity puri®ed as described (Sondell et
al, 1996). These antibodies are reactive towards human SCCE and pro-
SCCE, as well as murine SCCE.
Tissue extracts for the enzyme-linked immunosorbent assay were
prepared by homogenization of 200±400 mg frozen tissue in 1 ml dH2O
containing a mixture of protease inhibitors (Complete Protease Inhibitor
Cocktail Tablets, Boehringer Mannheim, Germany), followed by cen-
trifuging at 20,000 3 g for 30 min at 4°C. Protein concentrations were
determined by reaction with bicinchoninic acid, with bovine serum
albumin as standard. Sodium dodecyl sulfate±polyacrylamide gel electro-
phoresis, zymography, and immunoblotting were carried out as described
(Ekholm et al, 2000). Approximately 0.1 g of mouse skin was
homogenized in 10 ml of 1 M acetic acid and extracted overnight at
4°C. After clearing by centrifugation, extracts were aliquoted, lyo-
philized, and resolubilized in electrophoresis sample buffer. For histology
and immunohistochemistry (Sondell et al, 1996; Ekholm and Egelrud,
1998) samples were either formaldehyde ®xed and paraf®n embedded
according to routine protocols, or snap frozen after ®xation for 2 h in
formaldehyde.
Quantitative measurements of SCCE in tissue extracts were carried
out with a sandwich enzyme-linked immunosorbent assay with unconju-
gated and alkaline phosphatase conjugated SCCE-speci®c antibodies and
recombinant human pro-SCCE as standard.
Data were analyzed with a two-tailed, unpaired Student's t test.
RESULTS
The human and murine scce genes The amino acid sequences
(as deduced from cDNA) of human and murine SCCE show about
80% similarity (Hansson et al, 1994; BaÈckman et al, 1999). The
genomic organization of the human and murine scce structural genes
are schematically shown in Fig 1. Overall, the organization of the
exon±intron structure of the two genes is similar, but due to shorter
introns the murine gene is smaller. In the human gene the
translation initiation site is found 60 nt downstream the 5¢-end of
exon 2, and a potential TATA-box approximately 35 bp upstream
of exon 1. The murine initiation codon is positioned within the
second exon, 39 nt downstream of the intron±exon junction.
Phenotypic skin changes in SV40e±hscce transgenic mice In
order to study the effects of modi®ed scce expression we constructed
mice transgenic for the human scce gene under control of the SV40e
enhancer and promoter element. Mice transgenic for SV40e±hscce
integrated at a single site were obtained from three founders in the
C57BL/6JxCBA genetic background. At the age of 4±5 wk
macroscopic skin changes were apparent in mice of the Tg1010
line (Tg1010SV40e±hscce), whereas no obvious phenotype was seen in
mice of the two other lines. The skin changes were noted as a loss
of hair from a narrow zone around the eyes in mice 4±5 wk of age.
In older mice there was an apparent thinning of body hair in
general, and a luster-less appearance of the coat. We could see no
Figure 1. Organization of the human and murine structural
genes and the recombinant sv40e/hscce gene. The scce genes from
humans and mouse both contain six exons, here indicated as black
boxes, and have the translational start located in exon 2, and the stop
codon in exon 6. The most apparent difference between the structural
genes from the two species is that the introns are longer in the human
scce gene. To construct the recombinant gene, the sv40e transcriptional
regulatory element was inserted 20 nt upstream of the start codon of the
human scce gene, indicated by the arrow.
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gross changes in hair shaft morphology. On the back the skin
surface was covered with ®ne scales. From the age of 5±6 wk the
animals showed signs of itch with scratching, the frequency of
which increased with time. We therefore performed further studies
on Tg1010SV40e±hscce in which nontransgenic littermates and
transgenic mice from one of the two other lines, Tg107
(Tg107SV40e±hscce), served as controls.
Diagnostic necropsies were carried out with microscopic exam-
ination of brain, cerebellum, intestines (duodenum/jejunum,
ileum, colon, rectum), skin, heart, liver, lung, salivary gland,
spleen, thymus, and thyroid. In littermate controls (3 wk, n = 5;
5 wk, n = 5) and Tg107SV40e±hscce (5 wk, n = 4) no signi®cant
macro- or microscopic abnormalities were observed. In
Tg1010SV40e±hscce abnormalities were found in the skin of all
animals examined, but in no other organs or tissues. In mice 3 wk
of age (n = 4) skin changes included a mild to moderate epidermal
hyperplasia and hyperkeratosis, and a mild cellular in¯ammatory
reaction with mixed leukocytes in the upper dermis. In animals
5 wk of age (n = 4) the skin abnormalities were of the same type
but more pronounced with a marked acanthosis-like hyperplasia
and hyperkeratosis of the epidermis. In addition, the number of
mast cells in the dermis was increased in some of the animals.
Leukocyte invasion of the epidermis was occasionally found and
then manifested as small groups of granulocytes within the
thickened corni®ed layer, which at these sites was parakeratotic.
The level of expression of hscce in SV40e±hscce transgenic
mice correlate with phenotypic skin changes Analyses by
real-time quantitative PCR of hscce mRNA (Fig 2a) in a number
of tissues from transgenic mice consequently showed higher values
for Tg1010SV40e±hscce as compared with Tg107SV40e±hscce. The
highest relative levels were found in the intestines and lungs. The
most pronounced difference in hscce expression between the two
transgenic lines was seen in skin, in which the relative level of hscce
mRNA was about 25 times higher in Tg1010SV40e±hscce. Enzyme-
linked immunosorbent assay (Fig 2b) showed amounts of SCCE
protein close to or below the detection limit in tissues from
Tg107SV40e±hscce and normal controls. In Tg1010SV40e±hscce SCCE
protein was readily detected in several tissues, including the skin,
intestines, and lung, the relative level (ng per mg total protein)
being highest in the skin. It thus seemed plausible to us that the skin
changes seen in Tg1010SV40e±hscce but not in Tg107SV40e±hscce was
related to a higher expression of hscce mRNA and SCCE protein in
Tg1010SV40e±hscce.
Immunoblotting with SCCE-speci®c antibodies showed small
amounts of a component with a molecular mass similar to human
SCCE in the skin of control mice, whereas much higher amounts
of the corresponding component were found in the skin of
Tg1010SV40e±hscce (Fig 3a). A proteolytic enzyme corresponding to
human SCCE could be detected in extracts of skin from
Tg1010SV40e±hscce, but not in controls by zymography (Fig 3b;
the amounts of active murine SCCE are too low to be detected
under the experimental conditions used). These results suggest that
a fraction of the human pro-SCCE produced in the skin of
Tg1010SV40e±hscce is converted to proteolytically active enzyme.
This was supported also by the immunoblotting experiments
(Fig 3a), where small amounts of a component corresponding to
active human SCCE was found. In addition to SCCE, skin extracts
of Tg1010SV40e±hscce contained increased amounts of a proteolytic
enzyme with an apparent molecular mass of about 28 kDa, the
nature of which is presently not known.
Extended phenotypic analyses: overexpression of hscce
causes itchy dermatitis Three male Tg1010SV40e±hscce were
mated with wild-type C57BL/6J females, resulting in six litters
with a total of 40 mice. Of these 19 (eight Tg1010SV40e±hscce) were
killed at the age of 7±8 wk and 21 (11 Tg1010SV40e±hscce) were
followed to the age of 13±14 wk. In the latter group scratch
movements with the legs were quanti®ed.
Of the 11 transgenic mice followed for 13±14 wk, eight animals
(73%) showed signs of itch (at least one period of scratching with
hind or forepaws per minute) at the age of 10±11 wk. The
frequency of scratching varied. Whereas some animals showed
weak or moderate signs of itch, other animals spent most of their
time scratching (Fig 4). At the age of 13±14 wk there was a 7±10%
reduction in weight in transgenic mice as compared with wild-type
Figure 2. scce mRNA and SCCE protein in transgenic animals
and controls. (a)Real-time quantitative PCR analyses of recombinant
human scce mRNA in various tissue preparations from the transgenic
lines Tg1010SV40e±hscce (black bars) and Tg107SV40e±hscce (empty bars).
Analyses in triplicate were carried out on RNA samples comprising
pooled material from three animals from each line. The murine acidic
ribosomal phosphoprotein P0 was used as internal standard. Mean and
SD. (b)Enzyme-linked immunosorbent assay analyses of SCCE-protein in
various tissues from the transgenic lines Tg1010SV40e±hscce (black bars) and
Tg107SV40e±hscce (empty bars), and nontransgenic siblings (gray bars).
Analyses in triplicate were carried out on pooled extracts from three
animals from each line and controls. Mean and SD.
Figure 3. Pro-SCCE and active SCCE in skin from
Tg1010SV40e±hscce. Hu = extract of human plantar stratum corneum,
prepared as described (Ekholm et al, 2000); Tg = extract of skin from
Tg1010SV40e±hscce; Wt = extract of skin from wild-type littermate.
(a)Immunoblot with SCCE-speci®c antibodies, reduced samples.
Arrowheads denote, from top to bottom, glycosylated pro-SCCE, mixture
of unglycosylated pro-SCCE and glycosylated SCCE, and unglycosylated
SCCE (Hansson et al, 1994). Amount of sample applied corresponding to
0.1 mg and 4.5 mg of skin for Tg and Wt, respectively. (b)Zymography
in 12.5% acrylamide gel with 1% casein; nonreduced samples. Amount
of sample applied corresponding to 0.4 mg and 4.5 mg of skin for Tg
and Wt, respectively. Arrow denotes SCCE. To the far left (marked by
asterisks) molecular weight markers; from top 106, 81, 47.5, 35.3, 28.2,
and 20.8 kDa, respectively.
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litter mates (mean for males 27.0 g vs 30.0 g; p = 0.022; mean for
females 21.7 g vs 23.5 g; p = 0.033).
After killing the animals, tissues (dorsal skin, large and small
intestines, and lung) were prepared for microscopic analyses.
Examination of routinely processed skin samples was carried out
blindly (the examiner was not informed about genotype or
scratching behavior). In all cases but one, typical skin changes
allowed transgenic animals to be correctly identi®ed. Epidermal
thickness was 55 mm (SD = 21 mm; n = 19) for transgenic animals,
and 15 mm (SD = 2.6 mm; n = 21; p < 0.001) for controls. There
was no statistically signi®cant difference in epidermal thickness
between younger (7±8 wk) and older (13±14 wk) transgenic
animals. Other histologic ®ndings in the skin of transgenic animals
(Fig 5a, controls Fig 5b) were similar to those found at diagnostic
necropsy. In addition to the marked acanthosis and hyperkeratosis
there was an in®ltrate of in¯ammatory cells that was mainly
con®ned to the dermal part but occasionally seen also in the
epidermis. We also noted increased epithelial thickness of adnexal
structures (hair follicle walls, and sebaceous glands and ducts). No
differences could be detected by routine histology between
transgenic animals and normal littermates in other organs examined
(results not shown).
We next analyzed the pattern of SCCE expression by
immunohistology with SCCE-speci®c antibodies. In skin from
transgenic animals there was strong labeling of keratinocytes in the
suprabasal parts of interfollicular epidermis, including the thickened
corni®ed layer. In hair follicles and sebaceous ducts only luminal
parts, including the corni®ed lining of follicles and ducts, were
stained (Fig 5c). This was in marked contrast to basal cells of
interfollicular epidermis and the major peripheral parts of hair
Figure 4. Scratching behavior of scce-transgenic mice
Tg1010SV40e±hscce. Twenty-one mice (11 transgenics, ®ve females; 10
wild-type litter mates, two females) were observed every ®fth day for
45 d, starting when the mice were 5±6 wk of age. At each observation
point mice were transferred to individual cages, and episodes of
scratching with hind or front paws were counted during three 5 min
periods with 2.5 min lapsing from the transfer to the cage to the ®rst
counting, and between counting periods. The results for the three
observation periods were pooled and the number of episodes of
scratching per minute calculated. In a the number of episodes of
scratching (mean and SEM for all animals in each group) is shown, in b
the percentage of animals with at least one episode of scratching per
minute is given. Filled squares: Tg1010SV40e±hscce, ®lled triangles: wild-type
litter mates.
Figure 5. Histology and SCCE immunohistology of skin from
scce Tg1010SV40e±hscce and control; comparison with normal human
skin and chronic lesion of atopic dermatitis. Formaldehyde-®xed
and paraf®n-embedded samples. (a, b) Stained with hematoxylin and
eosin. (c±f ) Immunoperoxidase staining with SCCE-speci®c antibodies,
contra-staining with hematoxylin. (a, c) Tg1010SV40e±hscce, 5 wk of age.
(b, d) Nontransgenic littermate. (e) Atopic dermatitis. ( f ) Normal human
skin. Scale bar: 50 mm.
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follicles and sebaceous ducts and glands, where no or very weak
labeling by the antibodies was seen. The unexpectedly low
expression of SCCE in basal cells may suggest that regulatory
elements in the hscce gene overrides the SV40e promoter and direct
expression to more differentiated cells. In controls there was a
relatively weak labeling of high suprabasal cells, the stratum
corneum, and luminal parts of hair follicles (Fig 5d). This pattern
was similar to that previously described for normal human
epidermis (Ekholm and Egelrud, 1998). In the intestines of
transgenic animals SCCE-speci®c labeling was seen in irregularly
distributed epithelial cells. Stained cells were more numerous at the
tips of villi in the small intestine and in the luminal parts of colonic
epithelium. In the lungs of transgenic animals apical parts of
bronchiolar epithelial cells were weakly labeled. At higher antibody
concentrations there appeared to be diffuse labeling also of the
alveolar epithelium. No SCCE-speci®c staining was seen in the
intestines and lungs of control animals (results for intestines and
lung not shown).
Similarities between skin changes in Tg1010SV40e±hscce and
chronic lesions of atopic dermatitis in humans In previous
preliminary studies in humans with various skin diseases we had
noted that in chronic lesions characterized by acanthosis,
hyperkeratosis, and itch, the number of suprabasal epidermal cell
layers expressing SCCE was often increased. We had seen similar
changes in psoriasis (Ekholm and Egelrud, 1999). From these results
it was not possible to tell whether the changes in SCCE expression
played a signi®cant pathophysiologic role, or if they were merely
secondary to other changes in the epidermis. As the results
presented herein suggested that increased epidermal expression of
SCCE could by itself cause, in addition to severe itch, skin changes,
which in several aspects mimic chronic lesions seen in, e.g., atopic
dermatitis, we extended this study to include a number of patients
with this disease. Biopsies were taken from chronic eczematous
lesions on the ¯exural sides of lower arms of ®ve adults with atopic
dermatitis and processed for microscopy as above. Biopsies from
corresponding sites were obtained from volunteers. In routine
stained sections (not shown) the lesions showed, as expected,
marked acanthosis, hyperkeratosis, and a sparse dermal in®ltrate
consisting mainly of lymphocytes. Immunohistology with SCCE-
speci®c antibodies showed a drastic increase in the number of
labeled suprabasal cell layers as compared with controls (Fig 5e, f).
As regards the acanthosis, hyperkeratosis, and pattern of SCCE-
speci®c staining the differences seen between lesional and normal
skin were strikingly similar to those seen between the skin of
Tg1010SV40e±hscce and control mice.
DISCUSSION
In a number of previous studies we collected evidence that SCCE
may take part in stratum corneum turnover and desquamation.
Although in vitro experiments as well as the expression pattern and
tissue localization of SCCE suggested that SCCE may indeed take
part in desquamation, and that its function may be epidermis-
speci®c (Egelrud, 2000), this remained to be con®rmed by more
direct evidence. Further studies on the function of SCCE was
necessitated also by the fact that we had found expression of SCCE
at the RNA level also in a number of other tissues in addition to
skin, although at much lower levels (Hansson et al, 1994; BaÈckman
et al, 1999). By construction of a mouse transgenic for the human
scce gene linked to the SV40e promoter, we speculated that SCCE
would be produced in a number of organs, and that there would be
phenotypic changes that would be informative as regards the
physiologic function as well as effects of overexpression of SCCE.
The results presented in this report strongly suggest that the major
site of function of SCCE may be the skin and, in particular, the
epidermis. Another important ®nding was that SCCE may be
involved in skin pathophysiology.
We have thus shown that, whereas there is an elevated
expression of SCCE in lesions of human skin diseases such as
psoriasis (Ekholm and Egelrud, 1999) and atopic dermatitis,
overexpression of SCCE in the epidermis of transgenic mice
causes skin changes that have similarities to in¯ammatory skin
diseases in humans.
In SV40±hscce transgenic mice with phenotypic skin changes
aberrant expression of SCCE, RNA as well as protein, was found
also in other organs, especially the small and large intestine, and
lungs. The fact that no pathologic changes were seen in these
organs may be explained either by a resistance or unresponsiveness
to effects mediated by SCCE, or by a lack of SCCE-activating
enzymes in unaffected organs. SCCE (human as well as murine) is
produced as an inactive precursor, which is converted to active
protease by tryptic cleavage at a conserved site (Hansson et al, 1994;
BaÈckman et al, 1999). The enzyme responsible for SCCE activation
in the epidermis has not yet been identi®ed. Our ®nding that skin
of transgenic animals contained increased amounts of active SCCE
suggests that elevated levels of pro-SCCE in the epidermis also
leads to increased proteolytic activity. On the other hand, these
results also suggest that conversion of pro-SCCE to active SCCE is
under strict control, as only a minor fraction of the total SCCE
protein in the skin was present as active enzyme.
The mechanisms by which SCCE can cause a thickened
epidermis with hyperkeratosis, a dermal in¯ammatory in®ltrate,
and itch remain to be elucidated. According to the current view the
SCCE precursor is synthesized in high suprabasal epidermal
keratinocytes and stored in lipid-rich lamellar bodies. In the
process in which a terminally differentiated keratinocyte is
transformed from a viable cell to a corneocyte, i.e., a building
block of the corni®ed surface layer of the epidermis ± the stratum
corneum ± the contents of the lamellar bodies, including the
SCCE precursor, are secreted to the extracellular space, where
conversion of pro-SCCE to active protease is taking place (Sondell
et al, 1995). One possibility is that SCCE, which has been activated
as postulated, diffuses through the epidermis to the super®cial parts
of the dermis, and via its proteolytic activity induces epidermal
thickening, dermal in¯ammation, and activation of itch-mediating
nerve endings. Alternatively an increased proteolytic activity in the
transition zone between viable epidermal layers and the stratum
corneum may lead to the release of mediators, which diffuse to
other parts of the skin where they give rise to the observed changes.
A possible candidate may be interleukin 1b. We have recently
shown that this pro-in¯ammatory cytokine is activated by an
alternative mechanism in plantar and psoriatic epidermis, possibly
involving SCCE (Nylander-Lundqvist and Egelrud, 1997a, b;
Brattsand and Egelrud, 1998). The proliferative response of the
epidermis could be a result either of direct effects of released
mediators on keratinocytes, or an effect that is secondary to the
dermal in¯ammation. A third possibility is that the altered skin
phenotype re¯ects adaptive responses to a deterioration of the
barrier function of the stratum corneum caused by increased
proteolytic degradation of structures responsible for intercellular
cell cohesion in the corni®ed layer. Experiments aimed at
elucidation of these questions are under way.
Mechanisms of itch, and the molecular basis of differences
between in¯ammatory skin conditions as regards degree and quality
of associated pruritus, are poorly understood. The only fully
established in¯ammatory itch mediator is histamine, which,
however, is not likely to be responsible for the pruritus in diseases
other than various forms of urticaria (Greaves and Wall, 1996). It
has long been known that proteolytic enzymes, when injected
intradermally in humans, can cause itch (Arthur and Shelley, 1955).
The mechanisms involved may vary between enzymes used.
Whereas pancreatic trypsin and mast cell chymase appeared to cause
itch via release of histamine from mast cells, the itch caused by
papain and plasma kallikrein was likely not to involve histamine
(HaÈgermark et al, 1972; HaÈgermark, 1974). We have seen no
changes in scratching behavior in SCCE-transgenic mice treated
with the antihistaminic drug loratidine at 1.7 or 3.6 mg per g (T.
Egelrud and A. Ny, unpublished results), suggesting that histamine
is not a major cause of pruritus in these animals. The fact that signs
of itch were not seen before the age of 5 wk, whereas
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overexpression of SCCE was found also in younger animals, may
suggest that the pruritus was not a direct effect of SCCE, but was
secondary to the epidermal and dermal changes. In this context it
should be noted that conditions in experimental settings where
enzymes are injected intradermally may differ signi®cantly from the
situation in our SCCE-transgenic animals, in which production of
active protease may take place in high suprabasal parts of the
epidermis.
Recently a direct association between a defect in epidermal
barrier function and aberrant proteolysis in an inherited human
condition with severe skin disease has been described. Strong
evidence has been presented that the disease-causing mutations in
Netherton's syndrome are localized to the SPINK5 gene coding for
the multidomain serine protease inhibitor LEKTI (Chavanas et al,
2000; Sprecher et al, 2001). Furthermore, associations between
polymorphisms in SPINK5 and atopic dermatitis have been
reported (Walley et al, 2001). These results, together with our
present results, suggest that increased activity of serine proteases
present in the skin may indeed play a signi®cant part in skin
pathophysiology. Epidermal serine proteases such as SCCE should
therefore be explored as potential targets for new therapeutic
principles in in¯ammatory skin diseases.
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